» Articles » PMID: 34443380

Novel Putative Positive Modulators of α4β2 NAChRs Potentiate Nicotine Reward-Related Behavior

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2021 Aug 27
PMID 34443380
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The popular tobacco and e-cigarette chemical flavorant (-)-menthol acts as a nonselective, noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs), and contributes to multiple physiological effects that exacerbates nicotine addiction-related behavior. Menthol is classically known as a TRPM8 agonist; therefore, some have postulated that TRPM8 antagonists may be potential candidates for novel nicotine cessation pharmacotherapies. Here, we examine a novel class of TRPM8 antagonists for their ability to alter nicotine reward-related behavior in a mouse model of conditioned place preference. We found that these novel ligands enhanced nicotine reward-related behavior in a mouse model of conditioned place preference. To gain an understanding of the potential mechanism, we examined these ligands on mouse α4β2 nAChRs transiently transfected into neuroblastoma-2a cells. Using calcium flux assays, we determined that these ligands act as positive modulators (PMs) on α4β2 nAChRs. Due to α4β2 nAChRs' important role in nicotine dependence, as well as various neurological disorders including Parkinson's disease, the identification of these ligands as α4β2 nAChR PMs is an important finding, and they may serve as novel molecular tools for future nAChR-related investigations.

Citing Articles

Quantifying conditioned place preference: a review of current analyses and a proposal for a novel approach.

Yates J Front Behav Neurosci. 2023; 17:1256764.

PMID: 37693282 PMC: 10484009. DOI: 10.3389/fnbeh.2023.1256764.

References
1.
Teichert R, Memon T, Aman J, Olivera B . Using constellation pharmacology to define comprehensively a somatosensory neuronal subclass. Proc Natl Acad Sci U S A. 2014; 111(6):2319-24. PMC: 3926031. DOI: 10.1073/pnas.1324019111. View

2.
Jones C, Byun N, Bubser M . Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2011; 37(1):16-42. PMC: 3238081. DOI: 10.1038/npp.2011.199. View

3.
Henderson B, Grant S, Chu B, Shahoei R, Huard S, Saladi S . Menthol Stereoisomers Exhibit Different Effects on α4β2 nAChR Upregulation and Dopamine Neuron Spontaneous Firing. eNeuro. 2019; 5(6). PMC: 6325563. DOI: 10.1523/ENEURO.0465-18.2018. View

4.
Slemmer J, Martin B, Damaj M . Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000; 295(1):321-7. View

5.
Henderson B, Srinivasan R, Nichols W, Dilworth C, Gutierrez D, Mackey E . Nicotine exploits a COPI-mediated process for chaperone-mediated up-regulation of its receptors. J Gen Physiol. 2014; 143(1):51-66. PMC: 3874574. DOI: 10.1085/jgp.201311102. View